Left ventricular ejection fraction and cardiotoxicity: Is our ear really to the ground?

Journal of Clinical Oncology

Volumn 26, Issue 8, 2008, Pages 1201-1203

  Ewer, Michael S ^a   Lenihan, Daniel J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BRAIN NATRIURETIC PEPTIDE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; TRASTUZUMAB; TROPONIN I; TROPONIN T; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG SAFETY; EDITORIAL; HEART LEFT VENTRICLE EJECTION FRACTION; HEART STRESS; HUMAN; HUMAN CELL; HUMAN TISSUE; NEOPLASM; PRIORITY JOURNAL; RISK FACTOR; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; HEART; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; NOTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HEART; HEART FAILURE; HUMANS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 41649103274     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.8742     Document Type: Editorial

References (19)

1. Ewer MS, Ali MK, MacKay B, et al: A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving doxorubicin. J Clin Oncol 2:112-117, 1984
2. Ali MK, Ewer MS, Gibbs HR, et al: Late doxorubicin-associated cardiotoxicity in children: The possible role of intercurrent viral infection. Cancer 74:182-188, 1994
3. Ewer MS, Gibbs HR, Swafford J, et al: Cardiotoxicity in patients receiving trastuzumab (Herceptin): Primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol 26:96-101, 1999 (suppl 12)
4. Ewer MS Lippman S: Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity. J Clin Oncol 23:2900-2902, 2005
5. Jones LW, Haykowsky MJ, Swartz JJ, et al:, Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 50:1435-1441, 2007
6. Telli ML, Hunt SA, Carlson RW, Guardino AE: Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility. J Clin Oncol 25:3525-3533, 2007
7. Gottdiener JS, McClelland RL, Marshall R, et al: Outcome of congestive heart failure in elderly persons: Influence of left ventricular systolic function - The cardiovascular health study. Ann Intern Med 137:631-639, 2002
8. Cardinale D, Sandri M, Colombo A, et al: Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109:2749-2754, 2004
9. Lenihan DJ, Massey MR, Baysinger KB, et al: Superior detection of cardiotoxicity during chemotherapy using biomarkers. J Card Fail 13:S151, 2007
10. Ganz PA, Hussey MA, Moinpour CM, et al: Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol S8897. J Clin Oncol 26:1223-1230, 2008
11. Perez EA, Suman VJ, Davidson NE, et al: Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26:1231-1238, 2008
12. Tan-Chiu L, Yothers G, Romond E, et al: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811-7819, 2005
13. Suter TM, Procter M, van Veldhuisen DJ, et al: Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. J Clin Oncol 25:3859-3865, 2007
14. Ewer MS, Vooletich MT, Durand JB, et al: Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 23:7820-7826, 2005
15. de Korte MA, deVries EGE, Lub-de Hooge MN, et al: 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 43:2046-2051, 2007
16. Buzdar AU, Valero V, Ibrahim NK, et al: Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13:228-233, 2007
17. Cardinale D, Colombo A, Sandri MT, et al: Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114:2474-2481, 2006
18. Kalay N, Basar E, Ozdogru I, et al: Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48:2258-2262, 2006
19. Nakamae H, Tsumura K, Terada Y, et al: Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 104:2492-2498, 2005